POSIFLEX
As one of the world’s top five electronic Point of Sale (POS) system suppliers, Posiflex Technology is wrapping up a particularly banner year for 2022, benefiting from vigorous refurbishments in retail and hospitality industries during the post COVID-19 pandemic era. With excellent supply chain management and risk control, Posiflex has been less affected by the global supply crisis resulted from COVID-19 lockdowns and geographical conflicts on top of other risk factors during 2022, and the company is eyeing toward a further leap in its global-leading position.
World’s 5th Ranked POS Supplier Rises to the Challenge
According to the latest survey conducted by market intelligence firm RBR, Posiflex ranks as the 5th biggest POS brand in terms of shipped units throughout 2021, with its strongest presence in Southeast Asia, the Middle East, Africa and Europe. The RBR survey also found that Posiflex rose to 1st place in countries like India, the Philippines, Saudi Arabia and Greece, with its market share in India as high as 54%, and Saudi Arabia 42%.
Why Customers Choose Posiflex: Customization Capability, Quality and Delivery
A new customer feedback analysis conducted by RBR has revealed that Posiflex customers on a worldwide base are most satisfied with the company’s professional support including customization service, reliable quality, and stable delivery (effective and efficient logistics), ranking as the top 3 Posiflex advantages in the eyes of customers.
- Customization Service and better technical support
Posiflex is the only company among the top 5 POS suppliers to adopt a vertical integration strategy— it designs, manufactures, and sells POS systems and peripherals in-house, which means it is able to provide one-stop shopping service to customers as well as small volume customization to fit specific requirements of customers from different countries with various application scenarios and needs, including OS options, logo co-branding and special peripheral specs.
As Posiflex designs and manufactures products on its own, it is well-versed in technical details of its products and can be quicker and more helpful in responding to customers’ needs.
- Reliable quality
To provide reliable products, Posiflex takes care in selecting quality materials and conducts comprehensive tests before shipment, including vibration test, drop test, plus the industry’s highest standard full-system loading test in 40°C burn-in chamber for 12+ hours for all shipping products. Customers’ feedback also shows high satisfaction with Posiflex’s product quality.
- Good command of supply chain logistics
By merging various stages of production and supply chain into its own operations, Posiflex has also achieved better command of supply chain logistics with reduced need for outside entities. This, combined with a well-managed supplier network, has accumulated into better supply resilience for Posiflex to achieve more stable product deliveries and shorter delivery times than its competitors during the global supply shortage crisis in the past two years of the pandemic.
“Your success is our vision,” said Owen Chen, CEO of Posiflex, citing the company’s core values slogan. “We combine our technological advantages with customer needs and provide the most feasible products and services for partners and end users,” said Chen.
About POSIFLEX Group
Posiflex Group is a global leading Commercial Internet of Things (CIoT) enabler dedicated to providing O2O and embedded solutions. The group now is pillared by three business entities—Posiflex Technology, Portwell Inc. and US-based KIOSK Information Systems (KIS), specialized in the manufacturing of POS, embedded IPC and self-service kiosk respectively, with a common goal in pursuing a brave new world of smart commerce, where transactions become faster and more convenient physically or digitally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005378/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
2026 Mitsui Chemicals Catalysis Science Awards18.11.2025 03:00:00 CET | Press release
Online applications are open until December 25, 2025 Mitsui Chemicals, Inc. has announced that online applications for the 2026 Mitsui Chemicals Catalysis Science Award have been open since September 1, 2025. The application period will run from September 1 to December 25, 2025. Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 33 researchers within Japan and overseas. Past recipients include individuals who have gone on to be highly acclaimed worldwide, receiving honors such as the Nobel Prize in Chemistry and other prestigious Japanese and international awards. We welcome applications from a wide range of R&D fields, including solid catalysts,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
